1Gridelli C, Shepherd FA, Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence[ J ]. Chest, 2005,128 (2) :947 - 957.
2Burdette-Radoux S, Muss HB. Adjuvant chemotherapy in the elderly: whom to treat, what regimen? [ J ]. Oncologist, 2006,(3):234 -242.
3John V, Mashru S, Lichtman S. Pharmacological factors influencing anticancer drug selection in the elderly [ J]. Drugs Aging, 2003,20(10) :737 -759.
4Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study[ J ]. Cancer, 1998,82 (11) :2123 -2134.
5Balducei L. Guidelines for the management of the older cancer patient[ J ]. Cancer Treat Res, 2005,12 ( 4 ) :233 - 256.
6Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2 : results of an European Experts Panel[ J ]. Ann Oncol, 2004,15(3) :419 -426.
7Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial[ J ]. J Natl Cancer Inst, 2002,94 (3) : 173 - 181.
8Sweeney CJ, Zhu J, Sandier AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase Ⅱ trial in patients with metastatic nonsmall cell lung carcinoma [ J ]. Cancer, 2001,92 ( 10 ) :2639 - 2647.
9Biganzoli L, Aapro M. Adjuvant chemotherapy in the elderly[ J ]. Ann Oncol, 2003,14( Suppl 3 ) : 1 - 3.
10Early Breast Cancer Trialist's Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[ J ].Lancet, 2005,365 (9472) : 1687 - 1717.
3Baltali E,Ahundag K,Ozisik Y,et al.Weekly Taxotere in pretreated metastatic breast cancer:retrospective analysis of 52 patients[J].Tohoku J Exe Med,2004,203(3):205 -210.
4Gridelli C.Shepherd F.Chemotherapy for elderly patients with nonsmall cell lung cancer:a review of the evidence[J].Cheat,2005,128(2):947 -957.
5Buccheri G,Ferrigno D.Second-line weekly taxotere in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin[J].Lung Cancer,2004,45 (2):227-236.
6Tannock IF,de Wit R,Berry WR,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med,2004,351(15):1502 -1512.
7Kudoh S,Takeda K,Nakagawa K,et al.Phase Ⅲ study of docetaxel compared with vinorelbine in elderly patients with advanced nonsmall-cell lung cancer:results of the West Japan Thoracic Oncology Group Trial (WJTOG9904)[J].J Clin Oncol,2006,24 (22):3657-3663.
8Newman L A, Lee C T, Parekh L P, et al. Use of the national cancer data base to develop clinical trials accrual targets that are ap- propriate for minority ethnicity patients: a report from the american college of surgeons oneology group (ACOSOG) special population committee[J]. Cancer, 2006,106(1) :188-195.
9Mendiratta P, Armstrong A J, George D J. Current standard and in vestigational approaches to the management of hormone-refractory prostate cancer[J]. Rev Urol, 2007, 9(Suppl 1) :9 19.
10Bracarda S. Chemotherapy o{ postate cancer: potential role of do- eetaxelEJ3. Tumorigenesis, 2001,87(6) : 12-14.
